Pharmaceutical composition for treating cardiovascular and cerebrovascular disease
A technology for cardiovascular and cerebrovascular diseases and compositions, applied in the field of pharmaceuticals, can solve problems such as unclear chemical composition of Panax notoginseng saponins, increased incidence of adverse reactions, unclear mechanism of action, etc., to achieve reduced incidence of adverse reactions and improved drug efficacy Equivalent, ingredients clearly fixed effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
experiment example 4
[0099] Experimental Example 4: Comparative Study on the Toxicity of the Drug of the Present Invention and the Injection Preparation of Panax notoginseng Saponins
[0100] The toxicity tests of the present invention and related Panax notoginseng total saponins injection were compared with reference to the abnormal toxicity test method of the 2005 edition of "Chinese Pharmacopoeia" and with reference to the acute toxicity test method.
[0101] Table 8. Acute toxicity test results (LD50)
[0102]
[0103] Table 9. Abnormal toxicity test results
[0104]
[0105]
[0106] Compared with the above two test results, it is found that the product of the present invention is unexpectedly improved in terms of toxicity and abnormal toxicity, so that the safety of the product is obviously guaranteed, and the purpose of the invention is achieved.
experiment example 5
[0107] Experimental Example 5. Comparative Study on Hemolysis Test of Medicine of the Present Invention and Panax notoginseng Saponins Injection Preparation
[0108] Carry out the hemolysis test according to the test method of "Technical Guidelines for the Irritation and Hemolysis Research of Traditional Chinese Medicines and Natural Medicines", and observe the hemolysis and coagulation of the medicine of the present invention and related Panax notoginseng saponins injection samples at different concentrations.
[0109] 1. Test material
[0110] 1.1 Drugs: the powder injection prepared in Example 1 of the present invention, the injection prepared in Example 2, the powder injection prepared in Example 3, Xuesaitong injection, 100 mg / bottle, produced by Kunming Pharmaceutical Group Co., Ltd., batch number: 200701064-13; Xuesaitong for injection, 200mg / bottle, produced by Kunming Pharmaceutical Group Co., Ltd., batch number: 200701001-6.
[0111] Preparation of 2% erythrocyte su...
preparation Embodiment 1
[0124] Preparation Example 1: Ginsenoside Rg with a purity of 99.99% 1 and ginsenoside Rb 1 Preparation of the powder injection of the composition
[0125] Take Panax notoginseng and grind it into 1kg of coarse powder, add 5000ml of 70% ethanol to reflux and extract for 3 times, each time for 2 hours, collect the extract, filter, take the filtrate to recover ethanol until it has no alcohol smell, add water to make a solution containing 0.5g of crude drug per 1ml, On a macroporous resin column (type D macroporous resin, resin volume 4000ml, ratio of resin bed height to diameter is about 10), carry out gradient elution with water, 20%, 40%, and 60% ethanol respectively, and collect 40% (A contains ginsenoside Rg 1), 60% (B contains ginsenoside Rb 1 ) of the ethanol portion was evaporated to dryness. Add appropriate amount of methanol to dissolve part A, add 3 times the weight of silica gel to mix the sample, pass through an 80-mesh sieve after drying, put it on a silica gel ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| purity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More